TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Asthma Clinical Research Network (ACRN) Trial - Best Adjustment Strategy for Asthma in Long Term (BASALT)
Brief Summary: Asthma can be effectively controlled using inhaled corticosteroid medication. Treatment with inhaled corticosteroids often requires periodic adjustments to medication dosing and frequency levels. This study examines whether it is more beneficial to adjust corticosteroid treatment based on asthma symptoms and/or biomarkers of lung function versus standard medical guidelines.


Options:
A: Arm Label: High dose ICS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone Propionate | Arm Label: Low dose ICS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone Propionate | Intervention Type: DRUG; Name: Fluticasone Propionate; Assigned to Arm(s): Low dose ICS | Intervention Type: DRUG; Name: Fluticasone Propionate; Assigned to Arm(s): High dose ICS
B: Arm Label: Symptom-based adjustment; Type: EXPERIMENTAL; Interventions: Behavioral: Symptom-based adjustment | Arm Label: Biomarker-based adjustment; Type: EXPERIMENTAL; Interventions: Behavioral: Biomarker-based adjustment | Arm Label: Guideline-based adjustment; Type: EXPERIMENTAL; Interventions: Behavioral: Guideline-based adjustment | Intervention Type: BEHAVIORAL; Name: Symptom-based adjustment; Assigned to Arm(s): Symptom-based adjustment | Intervention Type: BEHAVIORAL; Name: Biomarker-based adjustment; Assigned to Arm(s): Biomarker-based adjustment | Intervention Type: BEHAVIORAL; Name: Guideline-based adjustment; Assigned to Arm(s): Guideline-based adjustment
C: Arm Label: Reference Strategy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Inhaled corticosteroids | Arm Label: Biomarker Strategy; Type: EXPERIMENTAL; Interventions: Drug: Inhaled corticosteroids, Procedure: eNO measurement | Intervention Type: DRUG; Name: Inhaled corticosteroids; Assigned to Arm(s): Biomarker Strategy, Reference Strategy | Intervention Type: PROCEDURE; Name: eNO measurement; Assigned to Arm(s): Biomarker Strategy
D: Arm Label: FeNO group; Type: N/A; Interventions: Device: measurement of exhaled NO is used to guide treatment | Arm Label: Symptom group; Type: N/A; Interventions: N/A | Intervention Type: DEVICE; Name: measurement of exhaled NO is used to guide treatment; Assigned to Arm(s): FeNO group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Asthma Clinical Research Network (ACRN) Trial - Best Adjustment Strategy for Asthma in Long Term (BASALT)
Brief Summary: Asthma can be effectively controlled using inhaled corticosteroid medication. Treatment with inhaled corticosteroids often requires periodic adjustments to medication dosing and frequency levels. This study examines whether it is more beneficial to adjust corticosteroid treatment based on asthma symptoms and/or biomarkers of lung function versus standard medical guidelines.


Options:
A: Arm Label: Symptom-based adjustment; Type: EXPERIMENTAL; Interventions: Behavioral: Symptom-based adjustment | Arm Label: Biomarker-based adjustment; Type: EXPERIMENTAL; Interventions: Behavioral: Biomarker-based adjustment | Arm Label: Guideline-based adjustment; Type: EXPERIMENTAL; Interventions: Behavioral: Guideline-based adjustment | Intervention Type: BEHAVIORAL; Name: Symptom-based adjustment; Assigned to Arm(s): Symptom-based adjustment | Intervention Type: BEHAVIORAL; Name: Biomarker-based adjustment; Assigned to Arm(s): Biomarker-based adjustment | Intervention Type: BEHAVIORAL; Name: Guideline-based adjustment; Assigned to Arm(s): Guideline-based adjustment
B: Arm Label: Placebo Budesonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Budesonide, Drug: Placebo Budesonide | Arm Label: Budesonide; Type: EXPERIMENTAL; Interventions: Drug: Budesonide, Drug: Placebo Budesonide | Intervention Type: DRUG; Name: Budesonide; Assigned to Arm(s): Budesonide, Placebo Budesonide | Intervention Type: DRUG; Name: Placebo Budesonide; Assigned to Arm(s): Budesonide, Placebo Budesonide
C: Intervention Type: DRUG; Name: inhaled fluticasone 750 mcg/day twice daily until 2 days without symptoms (maximum 15 consecutive days); Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Budesonide/formoterol Turbuhaler; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Salmeterol/fluticasone Diskus; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Non-inferiority Trial Comparing the Nevirapine-based Antiretroviral Therapy Versus the Standard Efavirenz-based ART for the Treatment of HIV-TB Co-infected Patients on Rifampicin-based Therapy (ANRS 12146 CARINEMO)
Brief Summary: The purpose of this study is to determine whether the use of Nevirapine in HIV patients already treated against tuberculosis by Rifampicin is as efficient and as well tolerated as Efavirenz.


Options:
A: Arm Label: Intervention 2: Nevirapine; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine | Arm Label: Intervention 2: Efavirenz; Type: ACTIVE_COMPARATOR; Interventions: Drug: Efavirenz | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): Intervention 2: Nevirapine | Intervention Type: DRUG; Name: Efavirenz; Assigned to Arm(s): Intervention 2: Efavirenz
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine based therapy, Drug: Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Efavirenz based therapy, Drug: Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z) | Intervention Type: DRUG; Name: Nevirapine based therapy; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Efavirenz based therapy; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z); Assigned to Arm(s): 1, 2
C: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Didanosine, Lamivudine, Nevirapine | Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Didanosine, Lamivudine, Efavirenz | Intervention Type: DRUG; Name: Didanosine, Lamivudine, Efavirenz; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Didanosine, Lamivudine, Nevirapine; Assigned to Arm(s): 2
D: Arm Label: Efavirenz; Type: EXPERIMENTAL; Interventions: Drug: efavirenz | Arm Label: Nevirapine; Type: EXPERIMENTAL; Interventions: Drug: nevirapine | Intervention Type: DRUG; Name: efavirenz; Assigned to Arm(s): Efavirenz | Intervention Type: DRUG; Name: nevirapine; Assigned to Arm(s): Nevirapine

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Situations That do Not Require Antibiotics for Acute Exacerbations of Mild-to-moderate Chronic Obstructive Pulmonary Disease
Brief Summary: The purpose of this study is to determine the effectiveness of antibiotic therapy for patients with acute exacerbations of mild-to-moderate chronic obstructive pulmonary disease.


Options:
A: Intervention Type: DRUG; Name: doxycycline; Assigned to Arm(s): N/A
B: Arm Label: lactose pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Sultamicillin; Type: EXPERIMENTAL; Interventions: Drug: Sultamicillin | Intervention Type: DRUG; Name: Sultamicillin; Assigned to Arm(s): Sultamicillin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): lactose pill
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Avelox (Moxifloxacin, BAY12-8039) | Arm Label: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Avelox (Moxifloxacin, BAY12-8039); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 2
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Amoxycillin and clavulanic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amoxicillin and clavulanic acid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Amoxicillin and clavulanic acid; Assigned to Arm(s): Amoxycillin and clavulanic acid

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Benefits and Risks of Early Antiretroviral Therapy in HIV-infected Adults in Abidjan, Côte d'Ivoire: Randomized Controlled Trial (ANRS 12136 TEMPRANO)
Brief Summary: The Temprano trial is based on the following assumptions:

* ART initiation at CD4 counts \<800/mm3 could significantly reduce the probability of severe HIV-related morbidity or death in the medium term.
* Tuberculosis and tuberculosis-related deaths are likely to represent a considerable proportion of morbidity and mortality among HIV-infected patients with high CD4 counts in sub-Saharan Africa. Therefore, 6-month Isoniazide Prophylaxis for Tuberculosis (IPT) and early ART could enhance each others efficacy.


Options:
A: Arm Label: I; Type: ACTIVE_COMPARATOR; Interventions: Drug: Antiretroviral medications | Arm Label: II; Type: EXPERIMENTAL; Interventions: Drug: Antiretroviral medications+Isoniazid prophylaxis | Arm Label: III; Type: EXPERIMENTAL; Interventions: Drug: Antiretroviral medications | Arm Label: IV; Type: EXPERIMENTAL; Interventions: Drug: Antiretroviral medications+Isoniazid prophylaxis | Intervention Type: DRUG; Name: Antiretroviral medications; Assigned to Arm(s): I | Intervention Type: DRUG; Name: Antiretroviral medications+Isoniazid prophylaxis; Assigned to Arm(s): II | Intervention Type: DRUG; Name: Antiretroviral medications; Assigned to Arm(s): III | Intervention Type: DRUG; Name: Antiretroviral medications+Isoniazid prophylaxis; Assigned to Arm(s): IV
B: Arm Label: One4All; Type: EXPERIMENTAL; Interventions: Behavioral: One4All | Arm Label: Standard of Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard of Care | Intervention Type: BEHAVIORAL; Name: One4All; Assigned to Arm(s): One4All | Intervention Type: BEHAVIORAL; Name: Standard of Care; Assigned to Arm(s): Standard of Care
C: Arm Label: Immediate ART; Type: EXPERIMENTAL; Interventions: Other: Strategy: Immediate ART | Arm Label: Deferred ART; Type: ACTIVE_COMPARATOR; Interventions: Other: Strategy: Deferred ART | Intervention Type: OTHER; Name: Strategy: Immediate ART; Assigned to Arm(s): Immediate ART | Intervention Type: OTHER; Name: Strategy: Deferred ART; Assigned to Arm(s): Deferred ART
D: Arm Label: Standard of care; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard of care | Arm Label: Same-day ART initiation with less frequent follow-up visits; Type: EXPERIMENTAL; Interventions: Other: Same-day ART initiation | Intervention Type: OTHER; Name: Same-day ART initiation; Assigned to Arm(s): Same-day ART initiation with less frequent follow-up visits | Intervention Type: OTHER; Name: Standard of care; Assigned to Arm(s): Standard of care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adherence and Intensification of Medications: A Population-Based Clinical Pharmacists Implementation Study Among Hypertensive Diabetes Patients
Brief Summary: Background: Good blood pressure (BP) control among patients with diabetes is essential in preventing diabetes complications and has been found to be not only cost-effective but cost-saving. Nonetheless, over 25% of VA patients with diabetes do not have adequate BP control. Among these poorly controlled patients, over 65% have problems with medication adherence or inadequate intensification of medications. We therefore propose a partnership with the VA Pharmacy Benefits Management (PBM) Office and VISN 11 to evaluate a tailored clinical pharmacist-based intervention to improve medication management, adherence and BP control.

Objectives: The specific objectives of this implementation study are: 1) To evaluate the effects of the intervention on blood pressure (primary outcome) and glycemic and lipid control (secondary outcomes); 2) To assess the impact of the intervention on patients' adherence to blood pressure, anti-hyperglycemic, and lipid-lowering regimens, and intensity of these regimens; 3) To evaluate the cost-effectiveness of the intervention compared to usual care; 4) To evaluate the level of attainment of intervention implementation, examine the process of intervention implementation, and determine the potential for sustainability.


Options:
A: Intervention Type: BEHAVIORAL; Name: Multidisciplinary team care; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Health coaching | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Health coaching; Assigned to Arm(s): 1
C: Arm Label: Training course for practice nurses in autonomy support; Type: EXPERIMENTAL; Interventions: Behavioral: Training course for practice nurses in autonomy support | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Training course for practice nurses in autonomy support; Assigned to Arm(s): Training course for practice nurses in autonomy support
D: Arm Label: Pharmacist management; Type: EXPERIMENTAL; Interventions: Behavioral: Clinical pharmacist-based intervention | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Clinical pharmacist-based intervention; Assigned to Arm(s): Pharmacist management

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adherence and Intensification of Medications: A Population-Based Clinical Pharmacists Implementation Study Among Hypertensive Diabetes Patients
Brief Summary: Background: Good blood pressure (BP) control among patients with diabetes is essential in preventing diabetes complications and has been found to be not only cost-effective but cost-saving. Nonetheless, over 25% of VA patients with diabetes do not have adequate BP control. Among these poorly controlled patients, over 65% have problems with medication adherence or inadequate intensification of medications. We therefore propose a partnership with the VA Pharmacy Benefits Management (PBM) Office and VISN 11 to evaluate a tailored clinical pharmacist-based intervention to improve medication management, adherence and BP control.

Objectives: The specific objectives of this implementation study are: 1) To evaluate the effects of the intervention on blood pressure (primary outcome) and glycemic and lipid control (secondary outcomes); 2) To assess the impact of the intervention on patients' adherence to blood pressure, anti-hyperglycemic, and lipid-lowering regimens, and intensity of these regimens; 3) To evaluate the cost-effectiveness of the intervention compared to usual care; 4) To evaluate the level of attainment of intervention implementation, examine the process of intervention implementation, and determine the potential for sustainability.


Options:
A: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Nurse-led blood pressure clinic; Type: EXPERIMENTAL; Interventions: Other: Nurse-led blood pressure clinic | Intervention Type: OTHER; Name: Nurse-led blood pressure clinic; Assigned to Arm(s): Nurse-led blood pressure clinic
B: Arm Label: Pharmacist management; Type: EXPERIMENTAL; Interventions: Behavioral: Clinical pharmacist-based intervention | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Clinical pharmacist-based intervention; Assigned to Arm(s): Pharmacist management
C: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Home Blood Pressure Monitoring Group; Type: EXPERIMENTAL; Interventions: Behavioral: Home Blood Pressure Monitoring | Intervention Type: BEHAVIORAL; Name: Home Blood Pressure Monitoring; Assigned to Arm(s): Home Blood Pressure Monitoring Group
D: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Other: High Intensity Intervention, Other: All- 6 month pharmacist intervention | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Low Intensity Intervention, Other: All- 6 month pharmacist intervention | Intervention Type: OTHER; Name: High Intensity Intervention; Assigned to Arm(s): Arm 1 | Intervention Type: OTHER; Name: Low Intensity Intervention; Assigned to Arm(s): Arm 2 | Intervention Type: OTHER; Name: All- 6 month pharmacist intervention; Assigned to Arm(s): Arm 1, Arm 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Methylphenidate for Apathy in Alzheimer's Dementia: A Controlled Study
Brief Summary: The purpose of the study is to determine the efficacy of methylphenidate over placebo in treating apathy in patients with Alzheimer's dementia. Apathy is one of the earliest and most profound disturbances that occur in Alzheimer's dementia (AD).

Hypotheses: 1. Methylphenidate (MPH) will improve apathy significantly more than placebo in AD.

2. Successful treatment of apathy will improve Instrumental Activities of Daily Living (IADLs), and caregiver burden.


Options:
A: Arm Label: Cholinesterase inhibitor only; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cholinesterase Plus Modafinil; Type: EXPERIMENTAL; Interventions: Drug: Modafinil | Intervention Type: DRUG; Name: Modafinil; Assigned to Arm(s): Cholinesterase Plus Modafinil | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cholinesterase inhibitor only
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate | Arm Label: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Arm 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Valproate | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Valproate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Risperidone-risperidone; Type: OTHER; Interventions: Drug: risperidone | Arm Label: Risperidone-Placebo; Type: OTHER; Interventions: Drug: risperidone | Arm Label: Placebo-Placebo; Type: OTHER; Interventions: Drug: risperidone | Intervention Type: DRUG; Name: risperidone; Assigned to Arm(s): Placebo-Placebo, Risperidone-Placebo, Risperidone-risperidone

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Double Blind Multi-Center Clinical Trial to Assess the Effects of Preoperative Long-Term Immunonutrition in Patients Listed for Liver Transplantation
Brief Summary: Patients with endstage liver disease characteristically are malnourished which is associated with poor outcome. Formulas enriched with arginine,ω3 fatty acids, and nucleotides potentially improve their nutritional status. This randomized placebo-controlled double blind multicenter clinical trial with longterm preoperative supplementation with such an enriched formula will evaluate evaluate effects of such formulas on patients' quality of life, survival, and posttransplant morbidities.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard ERAS group | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Post operative laxation (Magnesium Oxide) | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Preoperative metabolic conditioning postoperative nutritional supplementation | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Post operative laxation (Magnesium Oxide), Dietary Supplement: Preoperative metabolic conditioning postoperative nutritional supplementation | Intervention Type: DRUG; Name: Post operative laxation (Magnesium Oxide); Assigned to Arm(s): 2, 4 | Intervention Type: DIETARY_SUPPLEMENT; Name: Preoperative metabolic conditioning postoperative nutritional supplementation; Assigned to Arm(s): 3, 4 | Intervention Type: OTHER; Name: Standard ERAS group; Assigned to Arm(s): 1
B: Arm Label: Aminolaban EN; Type: EXPERIMENTAL; Interventions: Drug: Aminoleban EN | Arm Label: Control; Type: NO_INTERVENTION; Interventions: Drug: Aminoleban EN | Intervention Type: DRUG; Name: Aminoleban EN; Assigned to Arm(s): Aminolaban EN, Control
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Immunonutrition | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: food for special medical purposes (FSMP) | Intervention Type: DIETARY_SUPPLEMENT; Name: Immunonutrition; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: food for special medical purposes (FSMP); Assigned to Arm(s): 2
D: Arm Label: Test; Type: EXPERIMENTAL; Interventions: Dietary Supplement: PreOP Booster (oral nutritional supplement, food for special medical purposes) | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: PreOP Booster (oral nutritional supplement, food for special medical purposes) | Intervention Type: DIETARY_SUPPLEMENT; Name: PreOP Booster (oral nutritional supplement, food for special medical purposes); Assigned to Arm(s): Control, Test

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Stress, Immunity & Cervical Cancer: Biobehavioral Outcomes of a Randomized Trial
Brief Summary: The purpose of the study is to:

1. Test the efficacy of psychosocial telephone counseling (PTC) for cervical cancer survivors, compared to usual care.
2. Evaluate the longitudinal immune and neuroendocrine parameters in cervical cancer patients who have received PTC, compared to usual care.
3. Examine the longitudinal relationship between PTC associated modulations of quality of life (QOL) measures and biologic parameters (immune and neuroendocrine).


Options:
A: Arm Label: Brief; Type: EXPERIMENTAL; Interventions: Behavioral: Brief FOCUS Program | Arm Label: Extensive; Type: EXPERIMENTAL; Interventions: Behavioral: Extensive FOCUS Program | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Brief FOCUS Program; Assigned to Arm(s): Brief | Intervention Type: BEHAVIORAL; Name: Extensive FOCUS Program; Assigned to Arm(s): Extensive
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Testosterone | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Testosterone | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Testosterone | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Testosterone | Arm Label: 5; Type: ACTIVE_COMPARATOR; Interventions: Drug: Testosterone | Intervention Type: DRUG; Name: Testosterone; Assigned to Arm(s): 1, 2, 3, 4, 5
C: Arm Label: Minimal intervention control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Internet-based cognitive behavioral therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-based cognitive behavioral therapy. | Intervention Type: BEHAVIORAL; Name: Internet-based cognitive behavioral therapy.; Assigned to Arm(s): Internet-based cognitive behavioral therapy
D: Arm Label: Control Arm; Type: EXPERIMENTAL; Interventions: Behavioral: Telephone counseling, Behavioral: Telephone interview | Arm Label: Usual Care Arm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Telephone counseling, Behavioral: Telephone interview | Intervention Type: BEHAVIORAL; Name: Telephone counseling; Assigned to Arm(s): Control Arm, Usual Care Arm | Intervention Type: BEHAVIORAL; Name: Telephone interview; Assigned to Arm(s): Control Arm, Usual Care Arm

Answer: D